MedPath
HSA Product

LEXOTAN TABLET 3 mg

Product approved by Health Sciences Authority (SG)

Basic Information

LEXOTAN TABLET 3 mg

TABLET

Regulatory Information

SIN00382P

April 27, 1988

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 4, 2025

XN05BA08

Company Information

DKSH SINGAPORE PTE. LTD.

DKSH SINGAPORE PTE. LTD.

Active Ingredients

BROMAZEPAM

Strength: 3 mg

Detailed Information

Contraindications

**2.3 Contraindications** Lexotan is contraindicated in patients with: - known hypersensitivity to benzodiazepines or any of the excipients - severe respiratory insufficiency - severe hepatic impairment as benzodiazepines may precipitate hepatic encephalopathy - sleep apnea syndrome

Indication Information

**2.1 Therapeutic Indication(s)** Lexotan is indicated for anxiety, tension and other somatic or psychiatric complaints associated with the anxiety syndrome. It can also be used as an adjunct for treatment of anxiety or excitation associated with psychiatric disorders, such as mood disorders or schizophrenia. Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.

© Copyright 2025. All Rights Reserved by MedPath